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Purpose. Our recent studies show specific localization of long-circulating liposomes (LCL) within the
endosomal/lysosomal compartment of tumor-associated macrophages (TAM). Based on this finding, the
present study aims to investigate whether clinically applied LCL formulations such as Doxil (LCL-
encapsulated doxorubicin), have alternative mechanisms of action additionally to direct drug-mediated
cytotoxicity towards tumor cells.
Methods. The antitumor activity of Doxil was evaluated in B16.F10 melanoma-bearing mice, in the
presence and in the absence of TAM. To suppress TAM functions, liposomal clodronate (Lip-CLOD)
was injected 24 h before the actual treatment. The effect of Doxil on the levels of angiogenic factors was
determined using an angiogenic protein array. As positive control, the same experiments were conducted
with LCL-encapsulated prednisolone phosphate (LCL-PLP), a tumor-targeted formulation with known
strong anti-angiogenic/anti-inflammatory effects on TAM.
Results. Our results show that the antitumor efficacy of Doxil was only partially attributed to the
inhibition of TAM-mediated angiogenesis whereas LCL-PLP inhibited tumor growth through strong
suppressive effects on pro-angiogenic functions of TAM. As described previously, the main mechanism of
Doxil might be a cytotoxic effect on tumor cells.
Conclusions. Our findings suggest that the antitumor activity of Doxil does not depend mainly on the
presence of functional TAM in tumors.
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INTRODUCTION
Long-circulating liposomes (LCL) such as poly(ethylene
glycol) (PEG)-coated liposomes, possess a passive tumor-
targeting property (1,2). The long-circulation property of
intravenously (i.v.) administered LCL enables to exploit the
enhanced permeability of the tumor microcirculation for
extravasation into the tumor. LCL appear to accumulate in
the interstitium area surrounding capillaries and tend to be
taken up by tumor-associated macrophages (TAM; 3). TAM
play an essential role in processes that drive tumor angiogen-
esis and inflammation (4–6). As a result of the natural
tropism of LCL for TAM, angiogenic and tumor-associated
inflammatory processes are possibly significantly affected by
properly designed LCL-encapsulated drugs. Our previous
studies showed that prednisolone phosphate (PLP) encapsu-
lated in LCL (LCL-PLP) exerts strong inhibitory effects on
tumor growth via inhibition of tumor angiogenesis in
subcutaneous (s.c.) B16.F10 melanoma and C26 colon
carcinoma murine tumor models (3,7). Specific localization
of LCL within the endosomal/lysosomal compartment of
TAM has been observed (3). Recent results strongly suggest
that LCL-PLP act via their uptake by TAM leading to
suppression of TAM-mediated production of pro-angiogenic
factors (7). This also raises the question whether clinically
applied LCL formulations, such as Doxil™ (Caelyx™ in
Europe) (PEG-liposomes with encapsulated doxorubicin),
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ABBREVIATIONS: ANOVA, analysis of variance; bFGF, basic
fibroblast growth factor; EPR, enhanced permeability and retention;
FasL, Fas ligand; GC, glucocorticoids; G-CSF, granulocyte-colony
stimulating factor; GM-CSF, granulocyte-macrophage-colony
stimulating factor; IFN-γ, Interferon γ; IGF-II, Insulin growth factor
II; IL-1α, Interleukin 1α; IL-1β, Interleukin 1β; IL-6, Interleukin 6;
IL-9, Interleukin 9; IL-12 p40, Interleukin 12 p40; IL-12 p70,
Interleukin 12 p70; IL-13, Interleukin 13; i.v., intravenous
administration; LCL, long-circulating liposomes; LCL-PLP, long-
circulating liposome-encapsulated prednisolone disodium phosphate;
Lip-CLOD, a mixture of two types of clodronate liposomes:
clodronate-containing LCL and clodronate-containing large
negatively charged liposomes (ratio 1:1 (w/w)); MCP1, monocyte
chemoattractant protein-1; M-CSF, monocyte-colony stimulating
factor; MIG, monokine induced by IFN-γ; PBS, phosphate
buffered saline; PEG, Poly(ethylene glycol); PF4, platelet factor 4;
PLP, prednisolone disodium phosphate; s.c., subcutaneous
administration; SD, standard deviation; TAM, tumor-associated
macrophages; TIMP-1, tissue inhibitor of metalloproteinase 1;
TIMP-2, tissue inhibitor of metalloproteinase 2; TNF α, tumor
necrosis factor α; TPO, thrombopoietin; VEGF, vascular endothelial
growth factor.may have alternative mechanisms of action additionally to
their direct drug-mediated cytotoxicity towards tumor cells
(8). Therefore, this study aims to investigate whether the
mechanism of antitumor action of Doxil involves an anti-
angiogenic/anti-inflammatory activity resulting from modula-
tory effects on TAM functions in B16.F10 melanoma-bearing
mice. It is even not excluded that intracellularly accumulating
Doxil particles kill TAM, as it has been reported that
doxorubicin-containing liposomes could efficiently deplete
part of the liver macrophage population after i.v. administra-
tion to rats (9,10). To evaluate whether TAM play an
important role in the antitumor action of Doxil, clodronate-
containing LCL (mean size about 100 nm) were used as a tool
to deplete macrophages (11,12). Clodronate-containing lip-
osomes as macrophage-suppressive agents have already been
used in inflammatory and auto-immune diseases, where
macrophages have been suggested to play a critical role in
pathological processes (13). To study the antitumor activity
of Doxil towards tumors with suppressed TAM function,
tumor-bearing animals were pretreated with clodronate-
liposomes before the actual treatment with Doxil. In addi-
tion, the effect of Doxil treatment on the tumor levels of pro-
angiogenic and anti-angiogenic factors was determined in
B16.F10 melanoma-bearing mice with and without pretreat-
ment with liposomal clodronate (Lip-CLOD). As positive
control, the same experiments were conducted with LCL-
PLP, a tumor-targeted formulation with known strong anti-
angiogenic/anti-inflammatory effects on TAM (14).
MATERIALS AND METHODS
Preparation of LCL-PLP
L C Lw e r ep r e p a r e da sd e s c r i b e dp r e v i o u s l y( 3). In brief,
appropriate amounts of dipalmitoylphosphatidylcholine (Li-
poid GmbH, Ludwigshafen, Germany), cholesterol (Sigma, St.
Louis, MO, USA), and poly(ethylene glycol) PEG2000-
distearoylphosphatidylethanolamine (Lipoid GmbH) in a mo-
lar ratio of 1.85:1.0:0.15, respectively, were dissolved in ethanol
in a round-bottom flask. After lipid film formation, the film
was hydrated with a solution of 100 mg/ml prednisolone
disodium phosphate (PLP), (obtained from Bufa, Uitgeest,
The Netherlands). Liposome size was reduced by multiple
extrusion steps through polycarbonate membranes (Nuclepore,
Pleasanton, CA, USA) with a final pore size of 50 nm. Mean
particle size of the LCL was determined by dynamic light
scattering and found to be 0.1 μm with a polydispersity value
lower than 0.1. The polydispersity values obtained indicate
limited variation in particle size. Phospholipid content was
determined with a phosphate assay, performed on the organic
phase after extraction of liposomal preparations with chloro-
form, according to Rouser (15). Unencapsulated drug was
removed by dialysis in a Slide-A-Lyzer cassette with a
molecular weight cut-off of 10kDa at 4°C with repeated
changes of buffer. After extraction, the aqueous phase was
used for determining the glucocorticoid phosphate content by
high performance liquid chromatography as described previ-
ously (16). The type of column was RP18 (5 μm; Merck) and
the mobile phase consisted of acetonitril and water (1:3 v/v),
pH 2. The eluent was monitored with an ultraviolet detector
set at 254 nm. The detection limit for the high performance
liquid chromatography setup was 20 ng/ml. The liposomal
preparation contained about 5 mg PLP/ml and ∼60 μmol
phospholipid/ml. The encapsulation efficiency of PLP in LCL
was about 5% (80 μgP L P / μmol phospholipid). The drug
release from LCL was about 15%, at 37°C in the presence of
phosphate buffered saline (PBS) for 3 weeks.
Preparation of Clodronate-Containing Liposomes
(Lip-CLOD)
To deplete TAM, clodronate-containing LCL (3,12;
mean size about 0.1 μm and polydispersity value lower than
0.1) were prepared as described previously for LCL-PLP.
After lipid film formation, the film was hydrated with a
solution of dichloromethylene bisphosphonate, disodium
clodronate (Bonefos™ infusion (conc. 60 mg/ml); obtained
from Schering, Weesp, The Netherlands). To reduce recruit-
ment of new monocytes in tumors, large negatively charged
liposomes (mean size about 1 μm and polydispersity value
lower than 0.35) were used (17). Appropriate amounts of egg
phosphatidylcholine and egg phosphatidylglycerol (both
obtained from Lipoid GmbH, Ludwigshafen, Germany)
cholesterol (Sigma, St. Louis, MO, USA) in a molar ratio of
1.85:0.3:1 were dissolved in ethanol. The hydration of lipid
film was performed with 10 ml of clodronate or Bonefos
infusion (60 mg/ml). Liposomes were extruded twice through
a filter with a pore size of 8 μm. Phospholipid content was
determined with a phosphate assay, performed on the organic
phase after extraction of liposomal preparations with chloro-
form, according to Rouser (15). Unencapsulated drug was
removed by dialysis in a Slide-A-Lyzer cassette with a
molecular weight cut-off of 10kDa at 4°C with repeated
changes of buffer. After extraction, the aqueous phase was
used for determining the clodronate content by ultraviolet
spectrophotometry at 238 nm after formation of clodronate
complex with CuSO4 solution (18). Both types of liposomes
contained about 5 mg clodronate/ml and ∼70 μmol phospho-
lipid/ml with an encapsulation efficiency of clodronate about
8% (70 μg clodronate/μmol phospholipid).
Cells
B16.F10 murine melanoma cells were cultured as mono-
layers at 37°C in a 5% CO2-containing humidified atmo-
sphere in DMEM medium (Gibco, Breda, The Netherlands)
supplemented with 10% (v/v) heat-inactivated fetal calf
serum (Gibco), 100IU/ml penicillin, 100 μg/ml streptomycin
and 0.25 μg/ml amphotericin B (Gibco).
Murine Tumor Model
Male C57Bl/6 mice (6–8 weeks of age) were obtained
from Charles River (The Netherlands) and kept in standard
housing with standard rodent chow and water available ad
libitum, and a 12 h light/dark cycle. Experiments were
performed according to the national regulations and were
approved by the local animal experiments ethical committee.
For tumor induction, 1×10
6 B16.F10 melanoma cells were
inoculated s.c. in the right flank of syngeneic C57Bl/6 mice.
B16.F10 tumors became palpable at day 7 after tumor cell
inoculation.
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on the Antitumor Activity of Doxil
At 7 days after tumor cell inoculation, tumor size was
measured and tumor volume calculated according to the
formula V=0.52 × a
2 × b, in which a is the smallest and b, the
largest superficial diameter (in millimeter). The effect of
Doxil and free doxorubicin in presence or absence of
liposomal clodronate pretreatment on the growth of B16.
F10 melanoma in mice were studied. As positive control, the
same experiments were conducted with LCL-PLP, a tumor-
targeted formulation with known strong anti-angiogenic/anti-
inflammatory effects on TAM (7,14,19). In addition, as shown
previously (7), LCL-PLP exerts only minor cytotoxic effects
on B16.F10 murine melanoma cells in vitro.
To suppress macrophages a mixture of both clodronate
liposomes (ratio 1:1 (w/w); Lip-CLOD) at a dose of 25 mg/kg
(20) was injected i.v. at day 7 (when tumors became palpable;
24 h before the actual treatments). Doxil and free doxorubi-
cin were administered i.v. at a dose of 2 mg/kg at days 8 and
11 after tumor cell inoculation. LCL-PLP and free PLP at a
dose of 20 mg/kg were injected i.v. using the same dosing
schedule as for Doxil. This dosing schedule was selected
based on our previous studies on the effects of LCL-PLP and
Lip-CLOD on TAM (14). As controls, tumor-bearing mice
treated with PBS which did not receive Lip-CLOD treatment
were used. Four to five animals were used per experimental
group. On day 12, mice were sacrificed and tumor volumes
were measured.
Effect of Liposomal Clodronate Pretreatment
on the Anti-Angiogenic Actions of Doxil
To assess the effect of Doxil on TAM-mediated produc-
tion of angiogenic factors, the same experimental setup as
described above for testing antitumor activity of Doxil was
used. At day 12 after tumor cell inoculation, mice were
sacrificed and tumors were isolated. A screening of angio-
genic proteins present in tumor tissues was performed using
an angiogenic protein array (RayBio® Mouse Angiogenic
protein Antibody Array membranes 1.1 (RayBiotech Inc.
Norcross, GA)), according to manufacturers instructions (21).
Each membrane contains 24 types of primary antibodies
against certain angiogenic proteins. The tumor tissues for
each group were lysed in 30 min with cell lysis buffer
(RayBiotech), containing protease inhibitor cocktail (Sigma).
After obtaining the pooled tumor tissue lysates, the protein
content of the lysates was determined according to Peterson
(22). Subsequently, the array membrane was subjected to
different incubation steps, each for 2 h at room temperature
followed by five washing-steps. First, the array membrane
was incubated with 250 μg of protein from tissue lysates. Each
membrane was incubated with a mixture of secondary biotin-
conjugated antibodies, after which membranes were incubat-
ed with HRP-conjugated streptavidin. Thereafter, membranes
were incubated with a mixture of two detection buffers
(RayBiotech) for 1 min. X-ray film was exposed to the
membranes for 4 min and then the film was developed. The
experiment was perfomed in duplicate. Protein levels were
quantified measuring the color intensity of each spot using
GelPro Analyzer software, version 3.1, in comparison to
positive control spots already bound to the membrane.
Angiogenic protein levels in tumors were expressed as
percentage of the levels of the same proteins in tumors from
mice treated with PBS. Four to five animals were used per
experimental group. The final results represent mean ± SD of
two measurements.
Statistical Analysis
Data from different experiments were reported as mean ±
SD. For statistical analysis, Student’s t-test for independent
means was used. A value of P<0.05 was considered signifi-
cant. The differences between the overall effects of different
treatments on tumor growth were analyzed by one-way
ANOVA with Dunnett’s Multiple Comparison Test. The
differences between the effects of different treatments on
angiogenic factor levels were analyzed by two-way ANOVA
with Bonferroni correction for multiple comparisons using
GraphPad Prism version 4.02 for Windows, GraphPad
Software (San Diego, CA, USA).
RESULTS
Effect of Lip-CLOD Pretreatment on Antitumor Activity
of Doxil
To investigate whether the antitumor activity of Doxil on
B16.F10 melanoma model is dependent on the presence of
TAM in tumor tissue, B16.F10 melanoma-bearing mice were
pretreated with Lip-CLOD before i.v. administration of
Doxil. The purpose of Lip-CLOD pretreatment is to create
suppressed TAM functioning in the tumor before treatment
with Doxil. To this end, we prepared a mixture of two types
of clodronate liposomes (Lip-CLOD) in a ratio 1:1 (w/w). To
deplete TAM, clodronate was encapsulated in LCL (mean
size about 100 nm; 3,12). In addition, to reduce chemo-
attraction of new monocytes in tumors, clodronate-containing
large negatively charged liposomes (mean size about 1 μm)
were co-injected (17). Doxil treatment started 24 h after Lip-
CLOD pretreatment and involved an i.v. dose of 2 mg/kg at
days 8 and 11 after tumor cell inoculation. A separate positive
control animal group was treated with LCL-PLP, as it has
been shown recently that the antitumor activity of LCL-PLP
is largely based on inhibition of TAM-associated angiogenesis
and inflammation (14). LCL-PLP treatment (i.v. dose of
20 mg/kg at days 8 and 11 after tumor cell inoculation) started
also 24 h after Lip-CLOD pretreatment. The antitumor
activity of Doxil was compared to that of LCL-PLP, in the
presence and in the absence of Lip-CLOD pretreatment
(Figs. 1 and 2).
When Lip-CLOD pretreatment was not given, Doxil
treatment alone inhibited tumor growth by 80% (P<0.01)
compared to the growth of control tumors (tumors in mice
receiving only PBS). Similar inhibition of tumor growth (by
70%, P<0.01) was induced by LCL-PLP treatment (Fig. 1).
Lip-CLOD alone (i.e. not followed by Doxil or LCL-
PLP treatment) inhibited tumor growth by 65% (P<0.05)
compared to control tumors. When Lip-CLOD administra-
tion is followed by LCL-PLP treatment, no additional growth
inhibitory effect was seen (Fig. 2). When Lip-CLOD pre-
treatment is followed by Doxil treatment, clearly Doxil had a
1950 Banciu, Schiffelers and Stormstrong additional antitumor effect (by 73% tumor growth
inhibition P=0.0436) when compared to that induced by Lip-
CLOD-treated animals (Fig. 2). The combination treatment
with Doxil and Lip-CLOD is 3.5-fold more effective than Lip-
CLOD treatment alone.
Effect of Doxil on Angiogenic Protein Production; Influence
of Lip-CLOD Pretreatment
To assess the effect of Doxil on angiogenic protein
production in the B16.F10 melanoma model, with and
without Lip-CLOD pretreatment, angiogenic protein levels
in tumor tissue were studied. A screening of 24 angiogenic
proteins involved in angiogenesis, inflammation and apopto-
sis present in tumor tissue was performed using an angiogenic
protein array of RayBio® Mouse Angiogenic protein Anti-
body Array membranes 1.1 (RayBiotech Inc., Norcross, GA,
USA; 21). The effect of TAM suppression on the production
of angiogenic factors was verified in tumors from mice which
were treated with Lip-CLOD alone (i.e. not followed by
Doxil or LCL-PLP administration). Again LCL-PLP was
used as positive control, as this tumor-targeted formulation
has strong reducing effects on production of pro-angiogenic/
pro-inflammatory factors in tumors (7). When Lip-CLOD
pretreatment was not administered, Doxil reduced the level
of the majority of intratumoral pro-angiogenic factors only
slightly (Table I and Fig. 3). The strongest reduction after
Doxil treatment was noted for eotaxin, Fas ligand (FasL), and
vascular endothelial growth factor (VEGF; by 50–70%).
The production of most of the anti-angiogenic factors in
tumors was also only slightly affected by the Doxil treatment
(Table II and Fig. 3).
The LCL-PLP formulation, however, exerted strong
reducing effects on the intratumoral pro-angiogenic protein
production, in the absence of Lip-CLOD pretreatment
(Fig. 3). More specifically, LCL-PLP treatment reduced
expression of the pro-angiogenic factors GM-CSF, M-CSF,
IGF-II, IL-1α, IL-6, IL-12p40, bFGF (by 50–75%), and G-
CSF, IL-1β, eotaxin, FasL (by 75–100%; Table I). The
reduction exerted by LCL-PLP on most of the pro-angiogenic
proteins was much stronger (P=0.0086) when compared to
the result obtained with Doxil (Fig. 3). The level of the
majority of anti-angiogenic proteins was slightly suppressed
after LCL-PLP (Table II and Fig. 3). Only the intratumoral
production of IFNγ was strongly reduced (by 60%) by LCL-
PLP treatment.
Lip-CLOD treatment alone strongly reduced the level of
most of the pro-angiogenic tumor proteins (on average by
50%, P<0.0001 compared to control tumors; Figs. 3 and 4).
Interestingly, the level of two anti-angiogenic factors (TIMP-1
and TIMP-2) was also strongly reduced (about 60–100%, P<
0.0001; Fig. 3). When Lip-CLOD pretreatment was given,
Doxil treatment had no additional reducing effects on pro-
angiogenic (Fig. 4) and anti-angiogenic factor levels (data not
shown). However, when Lip-CLOD pretreatment was fol-
lowed by treatment with the positive control, LCL-PLP
formulation, the reduction of pro-angiogenic protein produc-
tion was somewhat enhanced (by 16%, P=0.0001; Fig. 4). No
additional effect of LCL-PLP on the level of anti-angiogenic
tumor proteins was seen (data not shown).
DISCUSSION
Doxil is a commercially available LCL formulation
containing the well-known antitumor agent, doxorubicin. It
has been shown to significantly enhance the doxorubicin
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Fig. 2. EffectofLip-CLODpretreatmentonantitumoractivityofDoxil
and LCL-PLP in murine B16.F10 melanoma model. All groups were
pretreated with Lip-CLOD 24 h before the actual treatment. Tumor
volumes at day 12 (day of sacrifice) were compared to tumor volumes in
mice treated with PBS. One-way ANOVA with Dunnett’s Multiple
Comparison Test was used; ns, not significant (P>0.05); *P<0.05. The
results represent mean±SD of 4–5m i c e .Lip-CLOD = treatment only
with Lip-CLOD, Lip-CLOD + Doxil = pretreatment with Lip-CLOD
followed by Doxil treatment, Lip-CLOD + LCL-PLP = pretreatment
with Lip-CLOD followed by LCL-PLP treatment.
Control Doxil LCL-PLP
0
250
500
750
1000
1250
1500
- Lip-CLOD pretreatment
t
u
m
o
r
 
v
o
l
u
m
e
 
(
m
m
3
)
Fig. 1. Antitumor activity of Doxil and LCL-PLP in B16.F10 murine
melanoma model when animals were not pretreated with Lip-CLOD.
Tumor volumes at day 12 (day of sacrifice) were compared to
volumes of tumors from mice treated only with PBS. One-way
ANOVA with Dunnett’s Multiple Comparison Test was used; **P<
0.01. The results represent mean±SD of 4–5 mice. −Lip-CLOD =n o
pretreatment with Lip-CLOD, Control = treatment with PBS, Doxil =
treatment with Doxil, LCL-PLP = treatment with LCL-PLP.
1951 Role of TAM in the Antitumor Activity of Doxillevels in the tumor and thereby antitumor activity, in various
mouse and human xenograft tumor models (10,23–26). This
study aimed to investigate whether the mechanism of the
antitumor activity of Doxil involves inhibition of tumor
angiogenesis through suppressive and possibly even lethal
effects on TAM, as i.v. administered LCL extravasating in
solid tumors have been shown to substantially localize in
TAM (3).
The anti-angiogenic actions of Doxil were compared
with those induced by LCL-PLP, a tumor-targeted formula-
tion with known strong anti-angiogenic/anti-inflammatory
activity in tumors (7,19). Recent studies reported that i.v.
administration of LCL-PLP results in strong inhibition of
tumor growth (3). The mechanism of antitumor action of
LCL-PLP appeared to be primarily based on a reduction
of intratumoral level of pro-angiogenic factors (7). The anti-
angiogenic effects exerted by LCL-PLP are enabled by the
tumor-targeting capability of LCL, which is a combined result of
the long circulation time of the liposomal formulation and the
enhanced permeability of tumor vasculature as compared to
healthy endothelium (7,27). LCL can extravasate through the
permeable pathological vasculature and thereby accumulate
into the malignant tissue (referred to as the “enhanced per-
meability and retention (EPR) effect”; 19). Once extravasated
into the tumor, LCL were observed to localize in the immediate
vicinity of tumor blood vessels and in the endosomal/lysosomal
c o m p a r t m e n to fT A M( 3). It is known that TAM have a main
role in tumor growth progression, being an important source of
inflammatory and angiogenic factors involved in all steps of
tumor angiogenesis (11,27–30).
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Fig. 3. Comparison of the anti-angiogenic actions of Doxil, LCL-PLP,
and Lip-CLOD in murine B16.F10 melanoma model. Results are
presented as % reduction of the levels of tumor angiogenic factors
ranging from 0% (white) to 100% (black) compared to the level of
angiogenic factors in control tumors. Control tumors are defined as
tumors from mice treated only with PBS. Doxil = treatment only with
Doxil; LCL-PLP = treatment only with LCL-PLP; Lip-CLOD =
treatment only with Lip-CLOD.
Table I. Effects of i.v. Administered Doxil and LCL-PLP on Pro-Angiogenic Protein Levels in s.c. B16.F10 Melanoma when Lip-CLOD
Pretreatment was Not Given
Pro-angiogenic factors
Reduction induced by
Doxil (% of reduction
as mean ± SD)
Reduction induced by LCL-PLP
(% of reduction as
mean ± SD)
Statistical
differences
Granulocyte-colony stimulating factor (G-CSF) 42.6±4.0 85.2±1.1 ***
Granulocyte-macrophage- colony stimulating factor (GM-CSF) 7.3±2.0 73.4±3.0 ***
Monocyte-colony stimulating factor (M-CSF) 8.0±1.0 50.0±0.1 ***
Insulin growth factor II (IGF-II) 24.5±5.3 70.5±0.7 ***
Interleukin 1α (IL-1α) 34.3±0.0 69.1±0.6 ***
Interleukin 1β (IL-1β) 17.2±6.4 76.2±5.2 ***
Interleukin 6 (IL-6) 21.5±9.2 69.9±1.2 ***
Interleukin 9 (IL-9) 15.5±2.4 47.4±9.2 ***
Interleukin 12p40 (IL-12 p40) 8.9±1.6 63.0±1.3 ***
Tumor necrosis factor α (TNF α) 37.3±2.3 22.0±9.8 **
Monocyte chemoattractant protein-1 (MCP1) 6.3±1.2 47.6±0.2 ***
Eotaxin 55.5±2.6 96.4±5.1 ***
Fas ligand (FasL) 66.1±8.3 86.0±8.9 ***
Basic fibroblast growth factor (bFGF) 39.7±3.5 52.6±1.8 *
Vascular endothelial growth factor (VEGF) 62.5±0.5 7.0±4.3 ***
Leptin 24.7±0.7 14.9±0.4 ns
Thrombopoietin (TPO) 38.0±0.9 3.3±2.0 ***
Pro-angiogenic factors are defined as proteins reported in literature to favor angiogenesis and tumor-associated inflammation. The protein
levels are compared to protein levels in control tumors (tumors from mice treated with PBS when the Lip-CLOD pretreatment was not given).
The results were analyzed for statistically significant differences between the effects of Doxil and LCL-PLP on the levels of pro-angiogenic
factors. A two-way ANOVA with Bonferroni correction for multiple comparisons was used. The results represent mean±SD of two
measurements
ns Not significant (P>0.05)
*P<0.05, **P<0.01, ***P<0.001
1952 Banciu, Schiffelers and StormTo investigate whether Doxil in addition to direct
cytotoxic effects on tumor cells, also exerts antitumor activity
via suppression of TAM, we investigated the effect of
pretreatment with Lip-CLOD (12,31,32) on the antitumor
activity of Doxil. Previous studies already showed the
feasibility of clodronate encapsulated in liposomes for
suppression of TAM activity from s.c. tumor tissue (11). Lip-
CLOD treatment alone strongly inhibited tumor growth.
Furthermore, Lip-CLOD induced strong reduction of the
production of most of the pro-angiogenic factors as well as of
certain anti-angiogenic factors (Fig. 3). These results clearly
suggest that TAM play a vital role in tumor growth by
producing angiogenic factors critical for tumor growth
progression.
In the absence of Lip-CLOD pretreatment, both Doxil
and LCL-PLP exerted strong tumor growth inhibitory effects.
Tumor growth was inhibited by 70–80% compared to the
growth of control tumors (Fig. 1).
In the presence of Lip-CLOD pretreatment, a signifi-
cantly stronger antitumor effect was observed after Doxil
administration. An additional antitumor effect was not
observed in case of LCL-PLP treatment (Fig. 2). With Lip-
CLOD already establishing antitumor activity via TAM
suppression, the lack of any additional effect confered by
the subsequent LCL-PLP treatment suggests that the LCL-
PLP localizing in the tumor area is not able to further
downregulate the functioning of the already suppressed
TAM, illustrating the effectiveness of the Lip-CLOD treat-
ment. The observation though that Doxil is able to induce
additional tumor growth inhibition, would indicate that its
antitumor activity does not depend on the presence of
functional TAM in tumor tissue, and that Doxil is killing
tumor cells via direct cytotoxic effects of doxorubicin on the
tumor cells (33–35).
This suggestion based on the tumor growth inhibition
results is confirmed by the results obtained at the level of the
intratumoral production of angiogenic proteins. Lip-CLOD
treatment alone appeared to strongly reduce the production
of particularly the pro-angiogenic factors, which is in good
agreement with its potent antitumor activity (Fig. 3). As it
was shown previously (7,14) LCL-PLP treatment alone
induces a similar strong degree of suppression, albeit the
intensity of the suppressive effect of both formulations varies
with the type of angiogenic factor. If the LCL-PLP is
administered after the anti-angiogenic Lip-CLOD treatment,
only a slight additive effect was seen, which is in line with the
similar anti-angiogenic mode of action of LCL-PLP via
suppressive effects on TAM (Fig. 4). Doxil, however, was
much less effective in reducing the angiogenic protein levels
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Lip-CLOD+Doxil
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Fig. 4. The influence of Lip-CLOD pretreatment on the effect of
Doxil and LCL-PLP on production of pro-angiogenic factors in
tumors. Results are presented as % average reduction of the level of
tumor pro-angiogenic factors compared to the level of pro-angiogenic
factors in control tumors. Control tumors are defined as tumors from
mice not treated with Lip-CLOD but treated with PBS. Mean±SD;
n=17 pro-angiogenic factor levels determined in duplicate per
experimental group, Lip-CLOD = treatment only with Lip-CLOD,
Lip-CLOD + Doxil = pretreatment with Lip-CLOD followed by Doxil
treatment, Lip-CLOD + LCL-PLP = pretreatment with Lip-CLOD
followed by LCL-PLP treatment. One-way ANOVA with Dunnett’s
Multiple Comparison Test was used; ns not significant (P>0.05),
and**P<0.01.
Table II. Effects of i.v. Administered Doxil and LCL-PLP on Anti-Angiogenic Protein Levels in s.c. B16.F10 Melanoma when Lip-CLOD
Pretreatment was Not Given
Anti-angiogenic factors
Reduction induced by
Doxil (% of reduction as
mean±SD)
Reduction induced
by LCL-PLP (% of reduction
as mean±SD) Statistical differences
Tissue inhibitor of metalloproteinase 1 (TIMP-1) 38.1±7.4 8.4±1.5 ***
Tissue inhibitor of metalloproteinase 2 (TIMP-2) 40.5±2.5 17.6±1.2 ***
Platelet factor 4 (PF4) 19.4±0.8 6.7±2.5 ns
Interleukin 12 p70 (IL-12 p70) 14.2±1.0 4.3±0.1 ns
Interleukin 13 (IL-13) 40.5±2.5 27.0±4.3 *
Interferon γ (IFN-γ) 36.0±1.0 60.2±3.6 ***
Monokine induced by IFN-γ (MIG) 38.7±0.6 25.6±4.4 *
The anti-angiogenic factors are defined as proteins reported in literature to impede angiogenesis and tumor-associated inflammation. The
protein levels are compared to protein levels in control tumors (tumors from mice treated with PBS when the Lip-CLOD pretreatment was not
given). The results were analyzed for statistically significant differences between the effects of Doxil and LCL-PLP on the levels of anti-
angiogenic factors. A two-way ANOVAwith Bonferroni correction for multiple comparisons was used. The results represent mean±SD of two
measurements
ns Not significant (P>0.05)
*P<0.05, ***P<0.001
1953 Role of TAM in the Antitumor Activity of Doxilas compared to LCL-PLP and Lip-CLOD, suggesting that the
strong antitumor activity of Doxil is not mediated by TAM-
related effects, although the mild degree of suppression of
angiogenic factor production observed might have been
caused by Doxil particles localizing in TAM and inhibiting
their function. That Doxil mainly acts via direct cytotoxic
effects on tumor cells, is indicated by the observation that
only Doxil treatment was able to strongly reduce the intra-
tumoral level of VEGF, a key angiogenic protein produced in
high amounts by melanoma cells (36). Both the anti-
angiogenic LCL-PLP and Lip-CLOD formulations did not
show this reducing effect on VEGF, supporting that both
formulations lack direct cytotoxic effects on melanoma cells.
Although localization of extravasated Doxil particles in
TAM is a realistic possibility, the antitumor activity is likely
for a large part based on other mechanisms. Doxorubicin may
be released from extracellularly localized Doxil particles and
subsequently entering tumor cells (37,38). In addition, Doxil
particles are likely being taken up by TAM (3). Intracellular
processing of Doxil particles within TAM involves degrada-
tion of the LCL bilayers within the endosomal/lysosomal
compartment. This degradation process likely leads to
liberation of doxorubicin molecules within TAM (33). As
doxorubicin molecules have been reported to be chemically
stable in the harsh environment encountered, they may pass
cellular membranes, and act intracellularly by inhibiting the
functionality and even viability of TAM explaining the
observed mild suppressive effects on the production of
angiogenic proteins. Alternatively, the liberated doxorubicin
molecules may be released in the extracellular tumor
interstitium, followed by passive diffusion into tumor cells,
and in this way contributing to the cytotoxicity of Doxil
towards tumor cells (33–35).
CONCLUSION
The present data suggest that the antitumor activity of
Doxil in the B16.F10 melanoma tumor model is not dependent
on the presence of functional TAM in tumor tissue.
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